BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
BioAtla (BCAB) has announced two poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30, 2025. The presentations will showcase the company's proprietary Conditionally Active Biologic (CAB) technology.
The first poster demonstrates CAB anti-Nectin4-antibody drug conjugate's superior efficacy compared to enfortumab vedotin analogue in multiple cancer models. The second presentation focuses on novel senolytic targets and CAB-based drug conjugates for targeting senescence-associated secretory phenotype cells.
The presentations will be held on April 27 and April 28, 2025, featuring research by authors including Jian Chen, Jing Wang, and others. The CAB technology aims to provide a new generation of biologics with improved safety margins and therapeutic index, specifically targeting acidic senescence in cancer and age-related diseases.
BioAtla (BCAB) ha annunciato due presentazioni poster al prossimo Meeting Annuale 2025 dell'American Association for Cancer Research (AACR) che si terrà a Chicago dal 25 al 30 aprile 2025. Le presentazioni metteranno in evidenza la tecnologia proprietaria dell'azienda, il Conditionally Active Biologic (CAB).
Il primo poster dimostra l'efficacia superiore del coniugato anticorpo-farmaco anti-Nectin4 basato su CAB rispetto all'analogo di enfortumab vedotin in diversi modelli tumorali. La seconda presentazione si concentra su nuovi target senolitici e coniugati farmacologici basati su CAB per colpire le cellule con fenotipo secretorio associato alla senescenza.
Le presentazioni si terranno il 27 e 28 aprile 2025 e includeranno ricerche di autori come Jian Chen, Jing Wang e altri. La tecnologia CAB mira a offrire una nuova generazione di biologici con margini di sicurezza e indice terapeutico migliorati, mirati specificamente alla senescenza acida nel cancro e nelle malattie legate all'età.
BioAtla (BCAB) ha anunciado dos presentaciones en formato póster en la próxima Reunión Anual 2025 de la Asociación Americana para la Investigación del Cáncer (AACR) que se celebrará en Chicago del 25 al 30 de abril de 2025. Las presentaciones mostrarán la tecnología patentada de la compañía, el Conditionally Active Biologic (CAB).
El primer póster demuestra la eficacia superior del conjugado anticuerpo-fármaco anti-Nectin4 basado en CAB en comparación con un análogo de enfortumab vedotin en múltiples modelos de cáncer. La segunda presentación se centra en nuevos objetivos senolíticos y conjugados farmacológicos basados en CAB para atacar las células con fenotipo secretor asociado a la senescencia.
Las presentaciones se llevarán a cabo el 27 y 28 de abril de 2025, con investigaciones de autores como Jian Chen, Jing Wang y otros. La tecnología CAB busca ofrecer una nueva generación de biológicos con márgenes de seguridad mejorados e índice terapéutico, dirigidos específicamente a la senescencia ácida en el cáncer y enfermedades relacionadas con la edad.
BioAtla (BCAB)는 2025년 4월 25일부터 30일까지 시카고에서 열리는 2025 미국암연구학회(AACR) 연례회의에서 두 건의 포스터 발표를 발표했습니다. 이번 발표에서는 회사의 독자적인 조건부 활성 생물학적 제제(CAB) 기술을 선보입니다.
첫 번째 포스터는 CAB 기반의 anti-Nectin4 항체-약물 접합체가 여러 암 모델에서 enfortumab vedotin 유사체보다 우수한 효능을 보임을 입증합니다. 두 번째 발표는 노화 관련 분비형 표현형 세포를 표적하는 새로운 세놀리틱 표적과 CAB 기반 약물 접합체에 초점을 맞춥니다.
발표는 2025년 4월 27일과 28일에 진행되며, Jian Chen, Jing Wang 등 연구진이 참여합니다. CAB 기술은 암과 노화 관련 질환에서 산성 노화를 특이적으로 표적하여 안전성 한계와 치료 지수를 개선한 차세대 생물학적 제제를 제공하는 것을 목표로 합니다.
BioAtla (BCAB) a annoncé deux présentations sous forme de posters lors de la prochaine Réunion Annuelle 2025 de l'American Association for Cancer Research (AACR) qui se tiendra à Chicago du 25 au 30 avril 2025. Ces présentations mettront en lumière la technologie propriétaire de l'entreprise, le Conditionally Active Biologic (CAB).
Le premier poster démontre l'efficacité supérieure du conjugué anticorps-médicament anti-Nectin4 basé sur CAB comparé à un analogue de l'enfortumab vedotin dans plusieurs modèles tumoraux. La seconde présentation porte sur de nouvelles cibles sénolytiques et des conjugués médicamenteux basés sur CAB pour cibler les cellules présentant un phénotype sécrétoire associé à la sénescence.
Les présentations auront lieu les 27 et 28 avril 2025 et présenteront des recherches menées par des auteurs tels que Jian Chen, Jing Wang et d'autres. La technologie CAB vise à offrir une nouvelle génération de biologiques avec une meilleure marge de sécurité et un indice thérapeutique amélioré, ciblant spécifiquement la sénescence acide dans le cancer et les maladies liées à l'âge.
BioAtla (BCAB) hat zwei Posterpräsentationen auf dem bevorstehenden Jahrestreffen 2025 der American Association for Cancer Research (AACR) angekündigt, das vom 25. bis 30. April 2025 in Chicago stattfindet. Die Präsentationen werden die firmeneigene Conditionally Active Biologic (CAB)-Technologie vorstellen.
Das erste Poster zeigt die überlegene Wirksamkeit des CAB-basierten Anti-Nectin4-Antikörper-Wirkstoff-Konjugats im Vergleich zu einem Enfortumab Vedotin-Analogon in mehreren Krebsmodellen. Die zweite Präsentation konzentriert sich auf neuartige senolytische Targets und CAB-basierte Wirkstoffkonjugate zur gezielten Bekämpfung von Zellen mit seneszenz-assoziiertem sekretorischem Phänotyp.
Die Präsentationen finden am 27. und 28. April 2025 statt und umfassen Forschungen von Autoren wie Jian Chen, Jing Wang und weiteren. Die CAB-Technologie zielt darauf ab, eine neue Generation von Biologika mit verbesserten Sicherheitsprofilen und therapeutischem Index bereitzustellen, die speziell saure Seneszenz bei Krebs und altersbedingten Erkrankungen anvisieren.
- None.
- None.
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) to be held at the McCormick Place Convention Center in Chicago, IL from April 25–30, 2025.
- Two abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology
- Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in lung, breast, pancreatic and urothelial patient derived cancer models
- CAB technology provides a new generation of biologics with an increased safety margin and therapeutic index, selectively targeting acidic senescence and senescence-associated secretory phenotype cells in cancer and age-related diseases
Presentation Details:
| Poster Title: | Identification of novel senolytic targets and development of Conditionally Active Biologic-based-drug conjugates for targeted senescence-associated secretory phenotype elimination in vivo |
| Authors: | Jian Chen, Jing Wang, Haizhen Liu, Gerhard Frey, Cathy Chang, William J. Boyle, and Jay M. Short |
| Poster Number: | 5 |
| Session Category / Title: | Molecular/Cellular Biology and Genetics / Senescence |
| Date / Time: | Sunday, April 27, 2025; 2:00–5:00 PM CDT |
| Location: | Poster Section 13 |
| Poster Title: | BA3361, A Tumor Selective, Conditionally Active Biologic (CAB) anti-Nectin4-ADC with a Novel NextGen Linker System Enhances Therapeutic Efficacy in Pancreatic Cancer |
| Authors: | Jing Wang, Jian Chen, Gerhard Frey, Haizhen Liu, Charles Xing, Kathryn Woodard, Cathy Chang, William J. Boyle, and Jay M. Short |
| Poster Number: | 10 |
| Session Category / Title: | Tumor Biology / Targeting the Tumor Microenvironment: A Brave New World |
| Date / Time: | Monday, April 28, 2025; 2:00–5:00 PM CDT |
| Location: | Poster Section 7 |
A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentations have concluded.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets includes methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. The Company also has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
What are the key findings of BioAtla's (BCAB) CAB technology presentations at AACR 2025?
When and where will BioAtla (BCAB) present their research at AACR 2025?
What cancer types does BioAtla's (BCAB) CAB anti-Nectin4-ADC show efficacy against?
How does BioAtla's (BCAB) Conditionally Active Biologic technology improve cancer treatment?
